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AHHS 389 Syllabus
Spring Semester 2014
Recent Advances in Clinical Medicine: Neurological Health
Class meets every Thursday at 12:10 p.m. in Skaggs Building 169
Course Coordinator: Kim Madson, PharmD, SB 318, 243-6635, pharmacy.ce@umontana.edu
January 30

Methamphetamine as a Neuroprotective Agent to
Treat Traumatic Brain Injury
Dave Poulsen, PhD
Research Professor, Biomedical & Pharmaceutical
Sciences
University of Montana
February 6 Seizures after Traumatic Brain Injury
Tom Swanson, MD
Montana Neurology
Missoula, Montana
February 13 Nutrition and the Brain: Evidence and Potential
Mechanisms
Sarah Miller, PharmD, BCNSP
Professor, Pharmacy Practice
University of Montana
February 20 Glial Brain Tumors
Richard Bridges, PhD
Professor and Chair, Biomedical & Pharmaceutical
Sciences
University of Montana
February 27 Multiple Sclerosis: Barriers to Medication
Adherence
Doug Allington, PharmD, BCPS
Associate Professor, Pharmacy Practice
University of Montana

March 27 Neurological Complications of HIV Infection
Gary Meyers, PharmD
Northwest AIDS Education and Training Center
Billings, Montana

April 3

April 10 From Benchside to Bedside: Understanding and
Treating Parkinson’s Disease
Fernando Cardoza, PhD
Associate Professor, Biomedical & Pharmaceutical
Sciences
University of Montana
April 17 Traumatic Brain Injury Medicine: A Brief Overview
with an Emphasis on Pharmacological Management
Bill Rosen, MD
Physical medicine & rehabilitation specialist
Missoula, Montana
April 24 Medication Challenges for Brain Injury Patients
Lois McElravy
Brain Injury Thriver
Missoula, MT

March 6

Alzheimer’s Disease and You
John Schaefer, DO
Montana Neurological Specialists
Missoula, Montana

May 1

Oxidative Stress and its Role in Underlying IschemicReperfusion-Induced Delayed Neuronal Death
Darrell Jackson, PhD
Associate Professor, Biomedical & Pharmaceutical
Sciences
University of Montana

March 13

Natural Products and Ayurvedic Therapies for
Neurological Disorders
Diana Lurie, PhD
Professor, Biomedical & Pharmaceutical Sciences
University of Montana

May 8

The Basic Neurological Exam: Why We Do What We
Do?
Ben Grass, MD
Medical Resident; Family Medicine Residency of
Western Montana
Ned Vasquez, MD
Director; Family Medicine Residency of Western
Montana

March 20

Menstrual Migraines: Potential Causes and
Modalities
Donna Beall, PharmD, BCPS
Professor, Pharmacy Practice
University of Montana
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Academic participants: There will be fourteen class meetings of AHHS 389 during the Spring Semester, 2014. To receive academic
credit for the course, you must attend 12 of the 14 classes. To verify your attendance, you must sign in on the roster that will be
circulated at each class meeting. If you fail to attend twelve complete sessions, you will receive a ‘NP’ in the course. If you find that
you must miss more than one session with valid reason, please see the Course Coordinator ASAP. Attendance will be logged in Moodle
weekly. Please pay close attention to your attendance record and report any discrepancies to the instructor. All students must practice
academic honesty. Academic misconduct is subject to an academic penalty by the course instructor and/or a disciplinary sanction by the
University. All students need to be familiar with the Student Conduct Code. The Code is available for review online at
http://life.umt.edu/vpsa/student_conduct.php.
Knowledge Assessment: Self-tests will be distributed at the conclusion of the program. Each pre/post learning assessment is
for participant use only and will not be graded.
Evaluations: Speaker evaluations will be distributed along with knowledge assessments as described above. Student feedback
on the quality and effectiveness of selected speakers, topics, teaching methodologies, and the overall course is invaluable to
the ongoing success of this academic and continuing professional education program. Completed speaker evaluations should
be returned to the Course Coordinator at the end of each class. Course evaluations will be distributed and collected at the
th
end of the final lecture on May 8 .
Goal: This lecture series for students, pharmacists, and health professionals will update participants on recent advances in
neurological health.
Learning Objectives: At the conclusion of each of the individual lectures, the participant will be able to:
1/30/14 – Methamphetamine as a Neuroprotective Agent to Treat Traumatic Brain Injury
 Explain the general consequences of brain injury.
 Explain preclinical approaches to the development of new drugs to treat Traumatic Brain Injury (TBI).
 Define important mechanisms of action for effective neuroprotective agents.
2/6/14 – Seizures After Traumatic Brain Injury
 TBA
2/13/14 – Nutrition and the Brain: Evidence and Potential Mechanisms
 Summarize evidence as to whether or not antioxidants, B vitamins, omega 3 fatty acids, gingko, and medical foods can
slow progressive of cognitive impairment.
 Classify common so-called “brain foods” as to how they might be beneficial to cognitive function.
2/20/14 – Glial Brain Tumors

TBA
2/27/14 – Multiple Sclerosis: Barriers to Medication Adherence
 Differentiate between definitions of compliance and adherence.
 If given a case, analyze which medication adherence barriers are present.
 If given a case, formulate a strategy to eliminate or mitigate common physician or patient-based medication adherence
barriers.
3/6/14 – Alzheimer’s Disease and You
 Identify current pharmacologic treatments for Alzheimer Disease and describe how they work.
 Recognize the risk factors for Alzheimer Disease.
 Describe which proteins are thought to play a role in the development of Alzheimer Disease.
 Name the genes known to play a role in Alzheimer Disease.
3/13/14 – Natural Products and Ayurvedic Therapies for Neurological Disorders
 Explain the definition of CAM (Complementary and Alternative Medicine).
 Identify several herbs and natural products that have been used traditionally in Ayurvedic medicine to treat neurological
diseases.
 Describe the scientific literature that either validates or invalidates these natural products.
 Define the role that neuroinflammation plays in neurological disease and how CAM therapies impact the CNS
inflammatory response.
 Describe the various Ayurvedic body therapies that are used to treat neurological dysfunction.
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3/20/14 – Menstrual Migraines: Potential Causes and Modalities
 Differentiate between the characteristics of a common migraine and menstrual migraine.
 Describe the non-pharmacologic and pharmacologic treatment modalities used to manage menstrual migraines.
3/27/14 – Neurological Complications of HIV Infection
 Identify common neurological manifestations of HIV infection.
 Describe specific symptoms or clinical markers of neurological decline in HIV+ patients.
 State the specific cells affected by HIV infection.
 Distinguish the difference between direct and indirect nervous systems effects of HIV infection.
 Define specific treatment options for opportunistic infections that involve the brain.
4/10/14 – From Benchside to Bedside: Understanding and Treating Parkinson’s Disease (PD)
 Describe the clinical, neurochemical, and histological manifestations of PD.
 List risk factor associated with the development of PD.
 List major therapeutic approaches.
 List major deficiencies in the treatment of PD.
 Name therapeutic approaches currently in development to treat PD.
4/17/14 – Traumatic Brain Injury Medicine: A Brief Overview with an Emphasis on Pharmacological Management
 Identify the basic nomenclature used in Brain Injury Medicine.
 Recognize the pathophysiology of the injury, especially mild traumatic brain injury.
 Describe the common potential consequences of a brain injury.
 Identify pharmacological agents used to improve outcomes in brain injury survivors.
4/24/14 – Medication Challenges for Brain Injury Patients
 State three common medication challenges for persons living with a brain injury.
 Identify two or three warning-signs or subtle clues that suggest a possible medication challenge/miscommunication exists
for brain injury patients.
 Describe two recommendations you can make to a person living with a brain injury if you recognize warning signs or
subtle clues suggesting a medication challenge/miscommunication.
5/1/14 – Oxidative Stress and its Role in Underlying Ischemic-Reperfusion-Induced Delayed Neuronal Death
 Distinguish between the different types of stroke pathologies.
 Describe how glutamatergic receptors, such as the AMPA receptor, contribute to delayed neuronal death.
 Describe how subjecting neuronal cells to ischemic-reperfusion can lead to oxidative stress.
 Describe how activation of oxidative stress signaling cascade can lead to synaptic plasticity and subsequent delayed
neuronal death.
5/8/14 – The Basic Neurological Exam: Why We Do What We Do?
 Differentiate the basic difference between upper and lower motor neuron lesions.
 Describe the basic physiology behind reflexes and their moderation.
 Describe the fundaments of a basic assessment of the cranial nerves.
 Identify the components of a basic assessment of peripheral strength, sensation, and reflexes.
 Describe the components of the basic mini mental status exam or the Montreal Cognitive Assessment.
 Be able to make a basic assessment of lesion location based on exam.

Disclosure of Potential Conflicts of Interest: Skaggs School of Pharmacy at The University of Montana did not receive
payment or services from a third party for any aspect of this activity and has no relationships (financial or other) with entities
or activities that could be perceived to influence, or that give the appearance of potentially influencing any portion of this
activity.
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